PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with advanced melanoma treated with PD-1 antibodies, nivol...

Descripción completa

Detalles Bibliográficos
Autores principales: Parakh, Sagun, Musafer, Ashan, Paessler, Sabrina, Witkowski, Tom, Suen, Connie S. N. Li Wai, Tutuka, Candani S. A., Carlino, Matteo S., Menzies, Alexander M., Scolyer, Richard A., Cebon, Jonathan, Dobrovic, Alexander, Long, Georgina V., Klein, Oliver, Behren, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220213/
https://www.ncbi.nlm.nih.gov/pubmed/34177913
http://dx.doi.org/10.3389/fimmu.2021.672521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220213/
https://www.ncbi.nlm.nih.gov/pubmed/34177913
http://dx.doi.org/10.3389/fimmu.2021.672521

Ejemplares similares